Q32 Bio Profit Margin

The latest profit margin for QTTB is 62.87% as of June 2026. That is above the Healthcare sector average of 14.34%. Investors often review this figure alongside Q32 Bio's historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, QTTB currently prints 62.87% for profit margin, while the sector average sits near 14.34%. That is roughly 338.3% above the sector mean. Large gaps often invite a closer look at Q32 Bio's growth, margins, and balance sheet.

Profit Margin shows how effectively Q32 Bio converts resources into returns. At 62.87%, QTTB may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting QTTB's profit margin (62.87%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Q32 Bio's profit margin against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.